Antibodies and protection against progressive to severe COVID-19: a meta-analysis.
Recently, global health institutions and public health systems have continued to advance service capacity building to provide stronger safeguards for public health. Vaccine-induced antibodies are an important indicator of protection against severe complications of COVID-19. Although the level of protection against severe COVID-19 remains high, the role of antibodies and other immune responses in protecting against severe complications remains unclear.
Understanding how vaccines prevent severe complications is important for future vaccine development. We carried out a systematic review of the literature to obtain a risk estimate of serious disease progression after SARS-CoV-2 infection. We summarized the risk of vaccine protection against serious disease progression from 25 published clinical studies.
We synthesized this clinical data with a meta-regression of 301 SARS-CoV-2 multicellular-induced and reactive titres datasets. The vaccine was found to provide a stronger protection against disease progression, with a higher level of protection when used for treatment than when treated with antigen-passive antibodies, and a 95% CI [0. 51,0.
64, significantly 0. 001) when used to treat individuals with a confirmed infection. The main methodological limitations were due to the measurement of Neutralization Titres and clinical outcomes in different studies, and possibly unmeasured confusion.
This work together demonstrates the relevance of vaccine-induced Neutralizing Antibodies to the protection against progression to severity of COVID-19 and at least partially explains the mechanism of this protection mechanism. However, there is still a protective barrier between the high level of protection provided by the vaccine and the severe COVID-19 protection caused by progression of the novel coronavirus. It should be noted that the above content is based on international public research, and is not a healthcare recommendation for HealthCop.
